Dapagliflozin

Generic Name
Dapagliflozin
Brand Names
Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
Drug Type
Small Molecule
Chemical Formula
C21H25ClO6
CAS Number
461432-26-8
Unique Ingredient Identifier
1ULL0QJ8UC
Background

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...

Indication

Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
Associated Therapies
-
Clinical Trials
Related News

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

Phase 4
Active, not recruiting
Conditions
SGLT2 Inhibitors
SLE
Lupus Nephritis
Interventions
Drug: placebo
Drug: dapagliflozin
First Posted Date
2023-03-01
Last Posted Date
2023-03-01
Lead Sponsor
Mansoura University
Target Recruit Count
100
Registration Number
NCT05748925
Locations
🇪🇬

Urology and Nephrology Center, Mansoura, Egypt

Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study

First Posted Date
2023-02-06
Last Posted Date
2024-03-05
Lead Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Target Recruit Count
100
Registration Number
NCT05713851
Locations
🇲🇽

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease

Phase 4
Recruiting
Conditions
End-stage Kidney Disease
Interventions
Drug: Dapagliflozin
First Posted Date
2023-01-17
Last Posted Date
2023-11-14
Lead Sponsor
University of Campinas, Brazil
Target Recruit Count
80
Registration Number
NCT05685394
Locations
🇧🇷

Centro de Pesquisas Clínicas, Campinas, SP, Brazil

Dapagliflozin With or Without Spironolactone for HFpEF

First Posted Date
2023-01-09
Last Posted Date
2024-07-11
Lead Sponsor
Universidade do Porto
Target Recruit Count
108
Registration Number
NCT05676684
Locations
🇵🇹

Unidade Local de Saúde Gaia/Espinho, Porto, Gaia, Portugal

🇵🇹

Centro Hospitalar Universitário São João, Porto, Portugal

Dapagliflozin Therapy In Cardiac Surgery

Phase 4
Recruiting
Conditions
Cardiac Surgery
Diabetes Mellitus, Type 2
Interventions
Drug: Dapagliflozin
First Posted Date
2022-11-18
Last Posted Date
2022-11-18
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
178
Registration Number
NCT05621551
Locations
🇨🇳

National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Dapagliflozin Effect on Rheumatic Mitral Stenosis

Phase 3
Not yet recruiting
Conditions
Rheumatic Heart Disease
Heart Failure
Mitral Stenosis
Interventions
Drug: Dapagliflozin
First Posted Date
2022-11-16
Last Posted Date
2022-11-21
Lead Sponsor
Universitas Sebelas Maret
Target Recruit Count
36
Registration Number
NCT05618223
Locations
🇮🇩

Sebelas Maret University Hospital, Sukoharjo, Central Java, Indonesia

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling

First Posted Date
2022-11-07
Last Posted Date
2023-02-28
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
98
Registration Number
NCT05606718
Locations
🇨🇳

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

🇨🇳

The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital, Meizhou, Guangdong, China

Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes

First Posted Date
2022-10-24
Last Posted Date
2022-10-24
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Target Recruit Count
60
Registration Number
NCT05591235

Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

First Posted Date
2022-10-06
Last Posted Date
2023-09-29
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
38
Registration Number
NCT05570305
Locations
🇨🇦

Montreal Clinical Research Institute, Montreal, Quebec, Canada

🇩🇰

Steno Diabetes Center, Copenhagen, Gentoft, Denmark

🇳🇱

Amsterdam Universitair Academisch Centrum, Amsterdam, Noord Holland, Netherlands

and more 4 locations

Effect of Dapagliflozin on VT in Patients With Heart Failure.

Phase 4
Not yet recruiting
Conditions
Heart Failure
Interventions
Drug: Placebo
Drug: Dapagliflozin
First Posted Date
2022-09-22
Last Posted Date
2022-09-22
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
120
Registration Number
NCT05550441
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy